Chris Ashton has become CEO of Etiologics in Oxford, UK. He joins the company from Orchid Bioscience, where he was CEO. Prior to that, he was commercial director of Inpharmatica and, previously, business development and marketing director at Oxford GlycoSciences.
At OGS, Ashton was responsible for initiating and negotiating partnerships with pharmaceutical and biotech companies. He also helped the company go public on the London Stock Exchange and raise $40 million.
Ashton also spent seven years at Applied Biosystems Europe. Ashton holds a BSc in biochemistry and a PhD in organic chemistry from the University of Manchester Institute of Science and Technology, and did postdoctoral research at the Massachusetts Institute of Technology. Etiologics provides novel mouse strains that can be used as disease models.
David Evjen has become CEO of Technologene, a startup company based in Lose Gatos, Calif. Evjen is the co-founder and former CEO of Med-Cor and Staff Outsourcing Solutions. He will be responsible for business development and focusing the company’s strategy, as well as guiding legal and public affairs functions. Technologene owns a patent for a process to produce industrial-grade proteins.